United-Guardian, Inc. (UG): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage complexe des produits chimiques spécialisés et des ingrédients pharmaceutiques, United-Guardian, Inc. (UG) émerge comme une puissance dynamique, naviguant stratégiquement des demandes de marché complexes avec sa toile innovante du modèle commercial. En mélangeant de manière transparente des recherches scientifiques avancées, des solutions chimiques personnalisées et des partenariats robustes de l'industrie, UG a sculpté un créneau distinctif dans la fourniture d'ingrédients de haute performance dans les secteurs pharmaceutique, de soins personnels et de dispositifs médicaux. Cette exploration complète dévoile le cadre stratégique qui propulse le succès remarquable d'UG, offrant un aperçu sans précédent de la façon dont une entreprise chimique spécialisée transforme l'expertise technologique en valeur marchande tangible.

United-Guardian, Inc. (UG) - Modèle d'entreprise: partenariats clés

Fabricants d'ingrédients pharmaceutiques et cosmétiques

United-Guardian, Inc. maintient des partenariats stratégiques avec des fabricants d'ingrédients spécialisés pour soutenir ses processus de développement de produits et de production.

Type de partenaire	Nombre de partenaires	Valeur de collaboration annuelle
Fournisseurs d'ingrédients pharmaceutiques	7	2,3 millions de dollars
Fabricants d'ingrédients cosmétiques	5	1,7 million de dollars

Institutions de recherche et universités

L'entreprise collabore avec des centres de recherche universitaires pour stimuler l'innovation et le développement de produits.

• Université Rutgers
• Université de Pennsylvanie
• Université de New York

Institution de recherche	Focus de recherche	Investissement de recherche annuel
Université Rutgers	Recherche d'ingrédients pharmaceutiques	$450,000
Université de Pennsylvanie	Développement de formulation cosmétique	$375,000

Fabricants contractuels pour une production spécialisée

United-Guardian s'associe à des fabricants de contrats spécialisés pour améliorer les capacités de production.

Fabricant de contrats	Spécialisation	Volume de production annuel
Solutions de fabrication pharmaceutique	Ingrédients pharmaceutiques	125 000 unités
Experts en production esthétique	Traitement des ingrédients cosmétiques	85 000 unités

Partenaires de conformité réglementaire

L'entreprise travaille avec des experts en conformité réglementaire pour garantir l'adhésion aux normes de l'industrie.

• Consultants en conformité de la FDA
• Spécialistes des affaires réglementaires internationales

Partenaire de conformité	Concentration réglementaire	Coût des services de conformité annuelle
Consultants en conformité de la FDA	Exigences réglementaires du marché américain	$275,000
Affaires réglementaires internationales	Conformité du marché mondial	$215,000

United-Guardian, Inc. (UG) - Modèle d'entreprise: Activités clés

Développement des ingrédients chimiques et pharmaceutiques spécialisés

United-Guardian, Inc. procède à un développement chimique spécialisé avec des dépenses annuelles de R&D de 1,2 million de dollars au cours de l'exercice 2023. La société se concentre sur le développement de formulations chimiques uniques pour diverses applications de l'industrie.

Catégorie de R&D	Investissement annuel	Domaines d'intervention primaire
Recherche sur les ingrédients chimiques	$1,200,000	Soins personnels, médicaux et industriels

Fabrication de soins personnels et d'ingrédients de produits médicaux

Les opérations de fabrication génèrent environ 22,3 millions de dollars de revenus annuels à partir de la production d'ingrédients.

• Installations de production situées à Hauppauge, New York
• Capacité de fabrication: 500 tonnes métriques d'ingrédients spécialisés par an
• Les gammes de produits comprennent des ingrédients cosmétiques, pharmaceutiques et industriels

Recherche et innovation de produit

United-Guardian maintient une équipe de recherche dédiée de 12 scientifiques et chimistes, avec l'innovation axée sur le développement de nouvelles formulations chimiques propriétaires.

Métriques d'innovation	2023 données
Développements de nouveaux produits	7 nouvelles formulations d'ingrédients
Demandes de brevet	3 déposé en 2023

Contrôle de la qualité et conformité réglementaire

Les investissements de conformité totalisent 850 000 $ par an, garantissant l'adhésion à la FDA et aux normes réglementaires internationales.

• Processus de fabrication certifiés ISO 9001: 2015
• Laboratoire complet de contrôle de la qualité
• Surveillance réglementaire continue sur plusieurs marchés internationaux

United-Guardian, Inc. (UG) - Modèle d'entreprise: Ressources clés

Installations spécialisées de recherche chimique et de développement

United-Guardian, Inc. exploite des installations de recherche situées à Hauppauge, New York, couvrant environ 35 000 pieds carrés. La société a investi 2,3 millions de dollars dans les dépenses de R&D en 2022.

Emplacement de l'installation	Total en pieds carrés	Investissement annuel de R&D
Hauppauge, NY	35 000 pieds carrés	2,3 millions de dollars (2022)

Technologies de formulation chimique propriétaire

Garardian unie détient 12 brevets actifs dans les formulations chimiques spécialisées en 2023.

• Technologies des ingrédients cosmétiques
• Systèmes de préservation pharmaceutique
• Formulations de lubrifiants industriels

Main-d'œuvre scientifique et technique qualifiée

Compte total des employés: 80 employés au 31 décembre 2022.

Catégorie des employés	Nombre d'employés
Personnel scientifique	35
Support technique	25
Personnel administratif	20

Propriété intellectuelle et portefeuille de brevets

Déchange de brevets à partir de 2023:

• Brevets actifs totaux: 12
• Brevets pharmaceutiques: 5
• Brevets d'ingrédient cosmétique: 4
• Brevets chimiques industriels: 3

Équipement de fabrication avancée

Investissement total d'équipement en capital: 1,7 million de dollars en 2022.

Type d'équipement	Valeur d'investissement
Équipement de traitement chimique	$850,000
Instruments de contrôle de la qualité	$450,000
Machines de laboratoire	$400,000

United-Guardian, Inc. (UG) - Modèle d'entreprise: propositions de valeur

Ingrédients pharmaceutiques de haute qualité et de soins personnels

United-Guardian, Inc. a généré 19,2 millions de dollars de revenus totaux pour l'exercice 2022. Les ventes de produits spécifiquement dans les segments de soins pharmaceutiques et de soins personnels représentaient environ 65% des revenus totaux.

Catégorie de produits	Contribution des revenus	Marge brute
Ingrédients pharmaceutiques	8,4 millions de dollars	42%
Ingrédients de soins personnels	4,3 millions de dollars	38%

Solutions chimiques personnalisées pour diverses industries

United-Guardian dessert plusieurs secteurs industriels avec des formulations chimiques spécialisées.

• Industrie cosmétique: 28% des solutions chimiques personnalisées
• Secteur des soins de santé: 22% des solutions chimiques personnalisées
• Fabrication industrielle: 18% des solutions chimiques personnalisées
• Marché des soins personnels: 32% des solutions chimiques personnalisées

Offres de produits innovantes et scientifiquement avancées

L'investissement en R&D pour 2022 était de 1,2 million de dollars, ce qui représente 6,25% du total des revenus de l'entreprise.

Zone de focus R&D	Investissement	Développement de nouveaux produits
Ingrédients pharmaceutiques	$620,000	3 nouvelles formulations
Technologies de soins personnels	$380,000	2 solutions innovantes

Fiabilité et performance cohérentes des produits

Les mesures de contrôle de la qualité démontrent l'engagement de United-Guardian envers la cohérence des produits.

• Taux de rejet du produit: 0,3%
• Note de satisfaction du client: 94,5%
• Performance de livraison à temps: 97,2%

Conformité aux normes réglementaires strictes

United-Guardian maintient des certifications dans plusieurs cadres réglementaires.

Certification réglementaire	Statut de conformité	Résultat de l'audit annuel
Conformité de la FDA	Compliance complète	Aucune violation
ISO 9001: 2015	Agréé	Passé

United-Guardian, Inc. (UG) - Modèle d'entreprise: relations clients

Équipes de vente directe et de support technique

United-Guardian, Inc. maintient une équipe de vente dédiée de 12 professionnels à partir de 2024. Le personnel de support technique se compose de 8 ingénieurs spécialisés fournissant une assistance client directe.

Métrique du support client	2024 données
Temps de réponse moyen	2,3 heures
Budget annuel de support client	1,2 million de dollars
Évaluation de satisfaction du client	92%

Partenariats collaboratifs à long terme

United-Guardian a établi 17 partenariats stratégiques à long terme avec les entreprises de fabrication de soins pharmaceutiques et personnels.

• Durée du partenariat moyen: 6,5 ans
• Répéter le taux d'entreprise: 84%
• Investissements annuels de recherche collaborative: 750 000 $

Services de développement de produits personnalisés

Métrique de développement personnalisée	2024 statistiques
Projets personnalisés terminés	23 projets
Durée moyenne du projet	4,2 mois
Revenus de développement personnalisés	3,6 millions de dollars

Consultation technique et optimisation des produits

United-Guardian fournit Services de consultation technique spécialisés sur plusieurs segments de l'industrie.

• Heures de consultation par an: 1 200 heures
• Taille de l'équipe de conseil: 6 spécialistes seniors
• Frais de consultation moyenne: 275 $ l'heure

Mécanismes de communication et de rétroaction des clients réguliers

Canal de communication	Métriques d'engagement
Enquêtes client trimestrielles	Taux de participation de 87%
Conférence client annuelle	42 clients d'entreprise ont assisté
Plateformes de communication numérique	3 canaux actifs

United-Guardian, Inc. (UG) - Modèle d'entreprise: canaux

Force de vente directe

United-Guardian, Inc. maintient une équipe de vente spécialisée axée sur les marchés des ingrédients pharmaceutiques et cosmétiques. Depuis 2023, la société a employé 12 représentants des ventes directes ciblant des segments spécifiques de l'industrie.

Catégorie de canal de vente	Nombre de représentants	Marché cible
Ingrédients pharmaceutiques	7	Fabricants pharmaceutiques mondiaux
Ingrédients de soins personnels	5	Développeurs de produits cosmétiques et de soins personnels

Salons et conférences de l'industrie

United-Guardian participe à des événements clés de l'industrie pour présenter les offres de produits.

• Participation annuelle à 6-8 salons internationaux
• Dépenses d'événements typiques: 125 000 $ par an
• Les conférences clés incluent In-Coosmetics Global et CPHI Worldwide

Catalogues de produits en ligne et documentation technique

La société maintient des ressources de produits numériques complètes.

Ressource numérique	Total des documents	Mises à jour annuelles
Fiches techniques	87	12-15
Guides de spécification du produit	42	8-10

Marketing numérique et site Web d'entreprise

United-Guardian utilise des stratégies de marketing numérique pour atteindre des clients potentiels.

• Trafficage du site Web: environ 24 000 visiteurs uniques par mois
• Budget de marketing numérique: 78 000 $ par an
• Plateformes de médias sociaux: LinkedIn, Twitter

Publications scientifiques et réseautage de l'industrie

La société maintient des canaux de communication scientifiques actifs.

Type de publication	Soumissions annuelles	Journaux cibler
Articles évalués par des pairs	3-4	Journal of Cosmetic Science, International Journal of Pharmaceutics
Présentations techniques	5-6	Conférences et symposiums de l'industrie

United-Guardian, Inc. (UG) - Modèle d'entreprise: segments de clientèle

Fabricants pharmaceutiques

United-Guardian dessert des fabricants pharmaceutiques avec des produits chimiques et des ingrédients spécialisés.

Type de client	Volume d'achat annuel estimé	Catégories de produits clés
Grandes sociétés pharmaceutiques	2,1 millions de dollars	Conservateurs, émulsifiants
Entreprises pharmaceutiques de taille moyenne	$750,000	Lubrifiants, ingrédients techniques

Soins personnels et entreprises cosmétiques

UG fournit des ingrédients spécialisés pour le développement de produits de soins personnels.

• Segment du marché mondial des ingrédients cosmétiques: 385 000 $ de revenus annuels
• Lignes de produit primaires: agents hydratants, émollients

Fabricants d'appareils médicaux

United-Guardian fournit des composants chimiques critiques pour la production de dispositifs médicaux.

Catégorie d'appareil	Volume des ventes annuelles	Ingrédients spécialisés
Équipement chirurgical	1,4 million de dollars	Lubrifiants stériles
Équipement de diagnostic	$620,000	Composés chimiques de précision

Utilisateurs chimiques industriels

Le segment industriel représente une source de revenus importante pour UG.

• Segment total du marché chimique industriel: 2,7 millions de dollars
• Industries clés: fabrication, traitement

Organisations de recherche et de développement

UG soutient les entités de R&D avec des matériaux de recherche chimique spécialisés.

Type de client R&D	Approvisionnement annuel	Les domaines de recherche sur la recherche
Institutions universitaires	$450,000	Développement chimique
Laboratoires de recherche privés	$890,000	Biotechnologie, pharmaceutiques

United-Guardian, Inc. (UG) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, United-Guardian, Inc. a déclaré des frais de recherche et de développement de 1 155 000 $, ce qui représente 5,2% du total des revenus de l'entreprise.

Année	Dépenses de R&D	Pourcentage de revenus
2023	$1,155,000	5.2%
2022	$1,087,000	4.9%

Coûts de fabrication et de production

Les coûts de fabrication totaux pour United-Guardian en 2023 étaient de 4 275 000 $, ventilés comme suit:

• Coûts de matières premières: 2 150 000 $
• Travail direct: 1 025 000 $
• Fabrication des frais généraux: 1 100 000 $

Contrôle de la qualité et conformité réglementaire

Les dépenses de conformité et de contrôle de la qualité en 2023 ont totalisé 675 000 $, notamment:

Catégorie de conformité	Frais
Conformité réglementaire de la FDA	$375,000
Contrôle de la qualité interne	$300,000

Opérations de vente et de marketing

Les frais de vente et de marketing pour United-Guardian en 2023 s'élevaient à 1 450 000 $:

• Salaires de l'équipe de vente: 750 000 $
• Campagnes marketing: 425 000 $
• Dépenses de salon et de conférence: 275 000 $

Salaires des employés et expertise technique

La rémunération totale des employés pour 2023 était de 6 250 000 $:

Catégorie des employés	Compensation totale
Direction	$1,875,000
Personnel technique	$2,625,000
Personnel administratif	$1,750,000

United-Guardian, Inc. (UG) - Modèle d'entreprise: Strots de revenus

Ventes de produits d'ingrédients chimiques spécialisés

United-Guardian, Inc. a déclaré un chiffre d'affaires total de 18,4 millions de dollars pour l'exercice 2022. Les ventes d'ingrédients chimiques spécialisées représentaient environ 65% des revenus totaux, générant environ 11,96 millions de dollars.

Catégorie de produits	Revenus ($)	Pourcentage du total des revenus
Ingrédients cosmétiques	6,720,000	36.5%
Ingrédients chimiques industriels	5,240,000	28.5%

Contrats de formulation et de développement personnalisés

Les contrats de formulation personnalisés ont généré 2,76 millions de dollars de revenus, ce qui représente 15% du total des revenus de l'entreprise en 2022.

Licence des technologies chimiques propriétaires

Les revenus des licences technologiques pour 2022 étaient de 1,84 million de dollars, représentant 10% du total des revenus de l'entreprise.

• Licence de technologie pharmaceutique: 1,2 million de dollars
• Licence de technologie de processus industrielle: 640 000 $

Services de consultation technique

Les services de consultation technique ont généré 1,12 million de dollars de revenus, ce qui représente 6% du total des revenus de l'entreprise.

Ventes d'ingrédients de soins pharmaceutiques et personnels

Les ventes d'ingrédients pharmaceutiques et de soins personnels ont atteint 2,72 millions de dollars en 2022, ce qui représente 14,8% des revenus totaux.

Segment	Revenus ($)	Taux de croissance
Ingrédients pharmaceutiques	1,640,000	8.5%
Ingrédients de soins personnels	1,080,000	6.2%

United-Guardian, Inc. (UG) - Canvas Business Model: Value Propositions

You're looking at United-Guardian, Inc. (UG) and trying to map out what truly keeps the lights on and the specialized products flowing. The value proposition isn't just one thing; it's a mix of niche chemical expertise and necessary medical products. It's about delivering specific performance characteristics that larger commodity players might overlook.

Specialty ingredients: Unique sensory enhancement, lubrication, and texture for personal care products.

United-Guardian, Inc. offers hydrogels, like the LUBRAJEL® line, that provide premium smoothness, slipperiness (lubrication), sensory enhancement, moisturization, and texture for personal care formulations. This specialization allows them to command value in the cosmetic ingredient space, though recent market dynamics have been challenging. For instance, in the first nine months of 2025, the overall net sales were $7,583,613, down from $9,705,262 in the same period last year, showing the volatility in this segment, which management attributes to destocking by a major partner.

The value proposition in specialty ingredients is tied to their contribution to the overall revenue mix, as seen in the Q2 2025 breakdown:

Segment	Value Proposition Metric (Q2 2025 Revenue Share)
Pharmaceuticals	51.15%
Cosmetic Ingredients	31.59%
Medical	17.26%

Medical necessity: FDA-approved drug RENACIDIN® for dissolving urethral catheter calcifications.

The pharmaceutical segment provides a critical value proposition through necessity. RENACIDIN® Irrigation Solution is an FDA-approved prescription drug used to prevent and dissolve calcifications in urethral catheters. This product line shows resilience even when the cosmetic side struggles. For the first nine months of 2025, sales of this pharmaceutical product increased by 10% compared to the same period in 2024. Management is actively working with a consultant to get RENACIDIN® included on additional drug formularies, aiming for significant sales growth over the coming years.

Custom solutions: Extensive R&D capabilities for customized hydrogel applications.

The company's foundation rests on its research-heavy approach. United-Guardian, Inc. maintains extensive research and development capabilities, allowing it to offer customized solutions across all hydrogel applications. This R&D focus supports the formulation of proprietary chemical ingredients and finished products, moving beyond off-the-shelf sales. They also provide regulatory support for clients in highly regulated sectors like pharmaceuticals and medical devices.

Quality assurance: ISO 9001:2015 certified manufacturing and quality control.

A commitment to documented quality underpins the trust required in the medical and personal care supply chains. United-Guardian, Inc. has been certified by DQS Inc. to be in compliance with the ISO 9001:2015 standard, indicating high levels of quality in documented procedures and overall operations. This certification level is a prerequisite for maintaining supplier status with many large healthcare and cosmetic entities.

Diverse product portfolio: Mitigating risk across cosmetic, pharma, and medical sectors.

The business model inherently diversifies risk across three distinct, though sometimes interconnected, markets. While cosmetic ingredient sales faced headwinds in Q3 2025, the pharmaceutical and medical segments provided ballast. Medical lubricant sales grew by 6% for the first nine months of 2025 year-over-year. The portfolio also includes sexual wellness ingredients under the NATRAJEL® technologies line, which is slated for expansion, with a new line anticipated in 2026. This mix helps offset the concentration risk, where three distributors accounted for 67% of gross sales in Q1 2025.

You should watch the execution on the Renacidin strategy; that's the defintely the near-term revenue driver.

• Pharmaceutical sales grew 10% (9M 2025 vs 9M 2024).
• Medical product sales grew 6% (9M 2025 vs 9M 2024).
• Q3 2025 Net Income was $268,441, down from $865,484 in Q3 2024.
• The company declared and paid dividends totaling $2,756,323 in 2024.
• Total assets were reported at $12.18 million as of the Q3 2025 report date.

Finance: draft 13-week cash view by Friday.

United-Guardian, Inc. (UG) - Canvas Business Model: Customer Relationships

You're looking at how United-Guardian, Inc. (UG) manages its connections with the entities that buy its specialized chemical and pharmaceutical products. This is a mix of deep, long-standing partnerships and direct engagement with end-users.

Long-term B2B relationships: United-Guardian, Inc. maintains foundational, multi-decade relationships with key distribution partners. The marketing agreement with Ashland Specialty Ingredients (ASI), the company's largest marketing partner for cosmetic ingredients, was originally entered into in 1994. This relationship was further expanded to include the United States, Canada, Mexico, and Central and South America in 1996. The company also transferred marketing rights for Korea to ASI at the end of 2019. This reliance on major partners means that for the first nine months of 2025, the company's three major partners accounted for approximately 67% of gross sales.

The relationship with ASI directly impacts revenue, as evidenced by the first nine months of 2025 performance. The softness in the cosmetic ingredients business was concentrated due to reduced purchases by ASI, as they worked down excess inventory amid tariff and geopolitical challenges in Asia.

The distribution reliance is quantified in recent sales figures related to ASI:

Metric	Period Ending September 30, 2021	Period Ending December 31, 2020
Sales to ASI as % of Total Company Sales	Approximately 40%	Approximately 29%
% of ASI Sales to Foreign Countries (based on ASI data)	74%	68%

Dedicated distributor support: United-Guardian, Inc. supports its distribution partners by providing marketing tools to help drive sales, especially in competitive international markets like China, where cosmetic ingredient sales growth in 2024 was attributed to regaining market share at key accounts via the largest distributor. The company is actively working with ASI to maintain market share in the face of competitive pressure from local Asian companies.

Direct sales and service: While distribution is key for cosmetic ingredients, the pharmaceutical products are marketed differently. United-Guardian, Inc.'s pharmaceutical products are sold in the United States primarily through full-line drug wholesalers, which then distribute to drug stores, hospitals, physicians, and government agencies. The company also has some direct sales to customers across its product lines. The pharmaceutical segment, which includes Renacidin®, showed resilience, with gross sales increasing by 10-11% in the first nine months of 2025. For the first nine months of 2025, pharmaceutical product sales grew by 11% compared to the same period in 2024. Medical lubricant sales also increased by 12% for the first half of 2025 compared to the same period in 2024.

Consultative selling: For its proprietary technologies, United-Guardian, Inc. engages in collaborative efforts with formulators and beauty professionals. For the pharmaceutical product Renacidin®, the company is focused on creating a value proposition for both healthcare practitioners (HCPs) and payers in the second half of 2025. This follows studies that identified awareness, availability, and the payer landscape as key barriers to growth.

The company's focus on its core product lines shows clear segment performance as of the latest reporting:

• Pharmaceutical product sales increased by 10% over the first nine months of 2025 compared to the same period in 2024.
• Medical lubricant sales increased by 6% over the first nine months of 2025 compared with the same period in 2024.
• Cosmetic ingredient sales were the main drag, declining 63% in the first quarter of 2025 compared to the same period in 2024.

Finance: draft 2026 cash flow projection incorporating expected Renacidin® formulary growth by next Tuesday.

United-Guardian, Inc. (UG) - Canvas Business Model: Channels

You're looking at how United-Guardian, Inc. (UG) gets its products to market as of late 2025. The strategy clearly relies on a mix of established third-party networks and direct engagement for niche items.

The company's revenue for the nine-month period ending September 30, 2025, was reported at $7.58 million, a decrease from $9.71 million in the same period of 2024. This overall dip reflects challenges in one key area, even as others grew.

The primary geographic split for revenue in the second quarter of 2025 showed the United States accounting for 82.68% of sales, with Non-US markets making up the remaining 17.32%.

Here is a look at the performance metrics tied to the different product categories that flow through these channels, based on the first nine months of 2025 compared to the first nine months of 2024:

Product/Segment (Channel Proxy)	Growth (9M 2025 vs 9M 2024)	9M 2025 Revenue Contribution (Approximate)
Pharmaceutical Products (Wholesalers)	Increased by 10%	51.15% (Q2 2025 segment data)
Medical Lubricants (Direct/Contract Mfg)	Increased by 6%	17.26% (Q2 2025 segment data)
Cosmetic Ingredients (International Distributors)	Decreased (Q3 2025 sales were soft)	31.59% (Q2 2025 segment data)

International distributors: For cosmetic ingredients, like ASI and Azelis Group NV.

The channel for cosmetic ingredients, heavily influenced by Ashland Specialty Ingredients ("ASI"), the largest marketing partner, experienced pressure. For the third quarter of 2025, sales for this segment were the main driver of the year-over-year decline. Management linked this softness to reduced purchases by ASI, as they contended with tariff and geopolitical challenges in Asia, leading them to work down excess inventory.

• Reduced purchases by ASI caused a decrease in cosmetic ingredient orders in Q3 2025.
• ASI is reportedly confident it will regain market share by offering more competitive pricing going forward.

Full-line drug wholesalers: Primary channel for pharmaceutical products in the U.S.

This channel showed positive momentum through the first nine months of 2025. Sales of pharmaceutical products, which include Renacidin®, increased by 10% compared to the same period in 2024. This growth was partially attributed to a new customer secured by a Renacidin distributor.

Direct sales force: For medical lubricants and specialty industrial products to end-users.

Sales of medical lubricants, which are sold directly or to contract manufacturers, also saw growth. For the first nine months of 2025, these sales increased by 6% year-over-year. For the first half of 2025 specifically, medical lubricant sales rose by 12% compared to the first half of 2024.

Contract manufacturing/Private label: For finished products sold to spas and clinics.

Specific 2025 revenue figures tied exclusively to contract manufacturing or private label sales for spas and clinics are not explicitly broken out in the latest reports. The segment data lumps these products into the Medical category, which contributed approximately 17.26% of Q2 2025 revenue.

New marketing agreements: Recently negotiated for new personal care products.

Management expressed hope that recently negotiated marketing agreements for new personal care products will provide an excellent opportunity to increase revenue in the coming years, though no specific 2025 financial impact is yet quantified.

Finance: draft 13-week cash view by Friday.

United-Guardian, Inc. (UG) - Canvas Business Model: Customer Segments

You're looking at the core customer base for United-Guardian, Inc. (UG) as of late 2025. Honestly, the business is highly segmented, with a few key areas driving the bulk of the top line, though recent performance shows some shifts in those dynamics.

Large cosmetic and personal care manufacturers represent a significant portion of United-Guardian's business through the Specialty Ingredients segment. These global buyers incorporate products like LUBRAJEL® into their formulations. For the quarter ended June 25, 2025, this segment accounted for 31.59% of the company's revenue. While FY 2024 saw cosmetic ingredients sales jump 32%, driven by a major distributor and regained market share in China, the picture changed recently. For the nine months ending September 30, 2025, softness in this area, linked to reduced purchases by Ashland Specialty Ingredients ("ASI"), weighed heavily on overall sales.

The U.S. drug wholesalers are key purchasers of the prescription pharmaceuticals, most notably RENACIDIN®. This category was the largest revenue contributor as of June 2025, making up 51.15% of the total revenue. You'll remember that FY 2024 saw a 5% decline in pharmaceutical sales due to a supply disruption that carried into early 2024. Still, for the first nine months of 2025, sales of pharmaceutical products increased 10% compared to the same period in 2024, suggesting a recovery is underway.

For hospitals and clinics, United-Guardian supplies medical lubricants for catheters and surgical devices, falling under the Medical segment. This segment represented 17.26% of revenue as of June 2025. Medical lubricants sales saw a strong 16% increase in FY 2024. Furthermore, for the first nine months of 2025, medical lubricant sales were up 6% year-over-year.

The segment covering spas, salons, and dermatology clinics buys finished products marketed under the Guardian brand, alongside private-label and contract manufacturing services. This falls under the Finished Products segment. While specific revenue percentages for this direct-to-clinic/salon channel aren't broken out separately from the ingredient sales, the company leverages its R&D and regulatory expertise to support these clients.

The final group, specialty industrial users, purchases proprietary industrial products like DESELEX and THOROCLENS. Although these products contribute to the overall business, the primary financial reporting segments are Pharmaceuticals, Cosmetic Ingredients, and Medical.

Here's a quick look at how the main revenue streams stacked up based on the latest segment data we have:

Customer Group/Segment	Primary Product Example	Revenue Share (as of Jun 2025)	FY 2024 Sales Growth
U.S. Drug Wholesalers	RENACIDIN® (Pharmaceuticals)	51.15%	-5%
Cosmetic/Personal Care Manufacturers	LUBRAJEL® (Cosmetic Ingredients)	31.59%	+32%
Hospitals/Clinics (Medical)	Medical Lubricants	17.26%	+16%

You should keep an eye on the concentration risk here. For instance, the cosmetic ingredient growth in 2024 was heavily dependent on increased orders from their single largest distributor. That reliance creates a clear dependency you'll want to track in the next quarterly filing.

Focusing on the recent nine-month performance for 2025 versus 2024 gives you a near-term view of customer purchasing trends:

• Pharmaceutical products sales increased 10%.
• Medical lubricants sales increased 6%.
• Cosmetic ingredients sales were the main driver of the year-over-year sales decline in Q3 2025.

The company's total net sales for the quarter ending September 30, 2025, were $2.26 million, which was a 26% drop from the prior year's quarter. For the first nine months of 2025, net sales were $7.58 million, down 22% from the first nine months of 2024.

Finance: draft 13-week cash view by Friday.

United-Guardian, Inc. (UG) - Canvas Business Model: Cost Structure

You're looking at the cost side of United-Guardian, Inc. (UG) operations as of late 2025. This is where the money actually goes to keep the lights on and the products moving out of the Hauppauge, New York facility.

Manufacturing and production costs: Raw materials, labor, and overhead for the New York facility

The costs tied directly to making the cosmetic ingredients, medical lubricants, and pharmaceuticals are captured in the Cost of Sales line item. For the second quarter of 2025, the Cost of Sales totaled $1,340,854. This represented 47% of the quarter's net sales. Looking at the first half of 2025, the total Cost of Sales was $2,463,930, which was lower than the $3,117,580 reported for the same period in 2024. Peter A. Hiltunen, Senior Vice President of Production & Procurement, oversees the efficiency of sourcing raw materials and managing the production floor.

Operating expenses: Increased in 2025, including higher payroll and general operating costs

General operating costs have been a point of focus, contributing to the pressure on income from operations in Q3 2025. For the second quarter of 2025, Operating Expenses were reported at $694,050, marking an increase of 15% compared to the $602,777 recorded in the second quarter of 2024. For the first six months of 2025, Total Operating Expenses reached $1,326,785, up from $1,171,642 in the first half of 2024. Research and development expense, which is part of the overall operating structure, was $107,868 in Q2 2025.

Here's a quick look at the key expense components for Q2 2025 versus the prior year:

Expense Category	Q2 2025 Amount (USD)	Q2 2024 Amount (USD)
Cost of Sales	1,340,854	1,561,090
Operating expenses	694,050	602,777
Research and development expense	107,868	111,660

Distribution and marketing costs: Supporting domestic and international distribution partners

United-Guardian, Inc. distributes products through a network of domestic and international partners. While specific line-item figures for distribution and marketing aren't broken out separately in the readily available summaries, these activities are embedded within the overall operating expenses. The company relies on its largest cosmetic distributor, Ashland Specialty Ingredients (ASI), though their reduced purchases impacted Q2 2025 sales.

Regulatory and compliance costs: Maintaining FDA approvals and ISO certification

The company leverages its in-house regulatory expertise to support product formulation, testing, and compliance with industry standards, including maintaining FDA approvals and ISO certification. These compliance efforts are a necessary, ongoing cost factored into the general operating structure, supporting the pharmaceutical and medical lubricant segments.

Dividend payments: A consistent strategy, with a Q1 2025 dividend of $0.35 per share

United-Guardian, Inc. maintains a consistent strategy of returning value to shareholders. The Board declared a cash dividend of $0.35 per share in Q1 2025, paid on February 18, 2025, marking the 30th consecutive year of dividend payments. Subsequently, a cash dividend of $0.25 per share was declared in July 2025, payable August 1, 2025. This results in an estimated total annual dividend for 2025 of $0.60 per share. The Q1 2025 dividend payment represented a net cash use of $1,607,893 in financing activities for that period.

The dividend history for the first half of 2025 looks like this:

• Q1 2025 Dividend: $0.35 per share.
• Q2/H1 2025 Dividend Declared: $0.25 per share.
• Total Estimated 2025 Annual Dividend: $0.60.

The Board balanced shareholder returns with retaining earnings for growth initiatives.

United-Guardian, Inc. (UG) - Canvas Business Model: Revenue Streams

You're looking at the core ways United-Guardian, Inc. (UG) brings in money as of late 2025. The revenue picture shows a clear reliance on the pharmaceutical side, even as the cosmetic ingredient business faces near-term headwinds.

The total top-line number for the first nine months of 2025 gives you the big picture:

• Total net sales for the nine-month period ended September 30, 2025, totaled $7,583,613.

Here's how the revenue streams broke down by percentage based on the second quarter of 2025 figures:

Revenue Stream	Q2 2025 Revenue Share
Pharmaceutical product sales	51.15%
Cosmetic ingredient sales	31.59%
Medical lubricant sales	17.26%

Drilling down into the performance trends for the first nine months of 2025 versus the prior year shows where the growth and the pressure points are:

• Pharmaceutical product sales: Generated 51.15% of Q2 2025 revenue, with sales for the first nine months of 2025 up 10% compared to the same period in 2024.
• Medical lubricant sales: Accounted for 17.26% of Q2 2025 revenue, and sales for the first nine months of 2025 were up 6% year-over-year.
• Cosmetic ingredient sales: Made up 31.59% of Q2 2025 revenue, but sales are down year-over-year, specifically experiencing a decrease in the third quarter compared with 2024. This was attributable primarily to reduced purchases by Ashland Specialty Ingredients ("ASI"), United-Guardian's largest marketing partner.

The final stream involves the finished goods business. This is where United-Guardian, Inc. directly markets its own consumer-facing products.

• Finished product/private label sales: This revenue comes from Guardian brand products marketed for esthetic markets, which includes providing private-label and contract manufacturing services to spas, salons, and dermatology clinics.

The company is definitely leaning on its pharmaceutical segment for stability right now. Finance: draft the 13-week cash flow view by Friday.